<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998956</url>
  </required_header>
  <id_info>
    <org_study_id>3rdxiangya@csu</org_study_id>
    <nct_id>NCT03998956</nct_id>
  </id_info>
  <brief_title>High-density Mapping-guided bOx Isolation and subsTrate Ablation</brief_title>
  <acronym>HOT</acronym>
  <official_title>Study of High-density Mapping-guided bOx Isolation and subsTrate Ablation for Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of high-density mapping guided atrial substrate ablation
      for persistent atrial fibrillation. 1/5 of the patients with persistent atrial fibrillation
      undergo pulmonary veins isolation, 2/5 of them pulmonary veins and box isolation while others
      undergo atrial substrate ablation apart from pulmonary veins and box isolation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sinus rhythm maintenance rate</measure>
    <time_frame>12 months</time_frame>
    <description>Holter is performed 12months after the procedure and heart rhythm is recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>left ventricular ejection fraction</measure>
    <time_frame>12 months</time_frame>
    <description>LVEF is evaluated by echocardiography 12months after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke or embolic events</measure>
    <time_frame>12 months</time_frame>
    <description>History of stroke or embolic events is taken at each follow-up during the period of 12 months after procedure, and if necessary, radiographic examinations will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrosis</measure>
    <time_frame>1 day</time_frame>
    <description>Atrial substrate mapping is performed before and after catheter ablation in one day to evaluate the atrial fibrosis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Remodeling</condition>
  <arm_group>
    <arm_group_label>Circumferential PV isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Circumferential PV isolation only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Circumferential PV and BOX isolation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Circumferential PV and BOX isolation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>circumferential PV and BOX isolation with substrate ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atrial substrate ablation apart from circumferential PV and BOX isolation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPVI</intervention_name>
    <description>Circumferential PV isolation only</description>
    <arm_group_label>Circumferential PV isolation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPVI+BOX</intervention_name>
    <description>Circumferential PV and BOX isolation</description>
    <arm_group_label>Circumferential PV and BOX isolation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPVI+BOX+SUB</intervention_name>
    <description>Atrial substrate ablation apart from circumferential PV and BOX isolation</description>
    <arm_group_label>circumferential PV and BOX isolation with substrate ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent signed.

          -  Age of 18 to 75 years old.

          -  Persistent or longstanding persistent atrial fibrillation (â‰¥7 days), which is
             confirmed by Holter in recent six months.

          -  Willing to have catheter ablation for atrial fibrillation.

        Exclusion Criteria:

          -  Accompanied by serious heart diseases including cardiac valvular diseases, congenital
             heart diseases, hypertrophic obstructive cardiomyopathy, acute myocardium infarction,
             unstable anginal pectoris and so on.

          -  Complete atrioventricular block.

          -  An acute stroke or contradiction of anti-coagulation.

          -  Hyperthyroidism.

          -  Having a history of catheter ablation of atrial fibrillation.

          -  Left atrial appendage thrombosis confirmed by transesophageal echocardiography.

          -  Pregnancy or lactation.

          -  Planning for pregnancy in the near future.

          -  Myopathy or active liver disease, including patients with sustained increase of serum
             transaminase of unknown reason and the ones with increased serum transaminase over
             three times the upper limit of normal.

          -  Patients of severe renal insufficiency with creatinine clearance lower than 30 ml/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

